El interés en corto de Entero Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Entero Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Entero Therapeutics (NASDAQ:ENTO) Bolsa, Informe de interés en corto

Entero Therapeutics

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Entero Therapeutics Inc

Entra ASA

ENTOURAGE HEALTH CORP by ENTOURAGE HEALTH CORP.

Entourage Health Corp

CFRA analyst Jonathan Sakraida maintains Ingersoll Rand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>) with a Hold and raises the price target from $85 to $95.

News

Price Target

Analyst Ratings

CFRA Maintains Hold on Ingersoll Rand, Raises Price Target to $95

Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has outperformed the market over the past 10 years by 19.23% on an annualized basis producing an average annual return of 30.74%. Currently, Tesla has a market capitalization of $798.69 billion. 
Buying $100 In TSLA: If an investor had bought $100 of TSLA stock 10 years ago, it would be worth $1,446.78 today based on a price of $250.01 for TSLA at the time of writing.
<h3>Tesla's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728077784_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

TSLA

Here's How Much You Would Have Made Owning Tesla Stock In The Last 10 Years

The phrase "the one percent" gets tossed around a lot in conversations about wealth and inequality, whether in politics, protests, or everyday chats. But what does it mean to be in the top 1%? Let's break it down by income and net worth to get a clearer picture of <a href="https://www.benzinga.com/personal-finance/24/09/40711869/how-rich-are-you-heres-the-net-worth-that-defines-upper-middle-and-lower-class">who's part of this exclusive group.</a>
Don't Miss:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? &#8211;<a href="https://www.benzinga.com/money/retire-5mil-nest-egg"> How does it compare to the average?</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
<li>This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a></li>
</ul>
What Income Puts You in the Top 1%?
To be in the <a href="https://www.benzinga.com/personal-finance/24/07/39652328/your-income-might-be-upper-class-and-you-dont-know-it-heres-the-salary-needed-to-reach-elite-sta">top 1% of earners</a> in the U.S., a household must bring in at least $591,550 a year. For a single individual, the cutoff is $407,500. Remember, these numbers are averages and can vary depending on where you live. For example, earning that much in New York City might not stretch as far as it does in other parts of the country.
The Top 1% by Net Worth
When it comes to net worth, the threshold is even higher. To be part of the top 1% in the U.S., a household's net worth needs to be at least $13.6 million. This measure includes everything you own – homes, investments, savings – minus debts.
Wealth tends to be a lot more unevenly distributed than income. Many households have little to no net worth, while the top tier sits on massive wealth. That's why net worth often gives a clearer picture of someone's financial status than income alone.
Trending: Beating the market through ethical real estate investing' — t<a href="https://www.benzinga.com/money/invest-with-roots">his platform aims to give tenants equity in the homes they live in while scoring 17.17% average annual returns for investors – here&#8217;s how to join with just $100</a>
Income vs. Net Worth: Which Tells the Real Story?
So, which is more important, income or net worth? It depends on what you're trying to measure. Income is great for understanding how much someone earns in a year, but net worth is the better gauge for long-term financial stability and overall wealth. Someone with a high income might not have a high net worth if they spend a lot or have significant debt, while someone with a lower income but solid investments could be much wealthier.
How Many People Are in the 1%?
As of the latest numbers, there are around 1.3 million households and about 1.8 million individual workers who fall into the top 1% in the U.S. That's a small slice of the population but represents a significant share of the country's wealth and income.
Trending: Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a>
State-by-State Variations
The income required to be in the top 1% varies significantly across states. For example:
<ul>
<li>Connecticut has the highest threshold at $952,902</li>
<li>Massachusetts follows at $903,401</li>
<li>California comes in third at $844,266</li>
<li>On the lower end, Mississippi has a threshold of just $254,362</li>
</ul>
See Also: <a href="https://www.benzinga.com/money/irs-finalizes-10-year-rule-adv">IRS Finalizes 10-Year Rule For Retirement Withdrawals, Making Things &#8216;Even More Insanely Complicated&#8217;</a>
Understanding <a href="https://www.benzinga.com/personal-finance/24/08/40378006/exactly-how-much-money-do-you-need-to-be-rich-heres-a-look-at-the-numbers">who makes up this elite group</a> isn't just about how much you earn right now but also what you've built over time.&nbsp;
Maybe you're not in the top 1%, or maybe you are – everyone's situation is different. Either way, <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">talking with a financial advisor</a> can be really helpful. They can guide you on where you stand and how to make the best decisions for your financial future, whether you're growing your wealth or looking to manage what you've got.
Read Next:
<ul>
<li>Founder of Personal Capital and ex-CEO of PayPal<a href="https://www.benzinga.com/money/evergreen-money"> re-engineers traditional banking with this new high-yield account — start saving better today.</a></li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>

Personal Finance

Are You Rich Enough To Be In The Top 1%? Here's Both The Income And Net Worth You Need to Rank Among The Wealthiest

STOCK RECEIVES 4TH SIGNAL IN LAST 5 TRADING SESSIONS FOR OVER 5% GAIN 
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="776" height="797" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/04200903/Screen-Shot-2024-10-04-at-4.09.32-PM.png" alt="" class="wp-image-1972" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/04200903/Screen-Shot-2024-10-04-at-4.09.32-PM.png 776w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/04200903/Screen-Shot-2024-10-04-at-4.09.32-PM-292x300.png 292w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/04200903/Screen-Shot-2024-10-04-at-4.09.32-PM-768x789.png 768w" sizes="(max-width: 776px) 100vw, 776px" /></figure>
Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 10:37AM on October 4th, a significant trading signal occurred for Meta Platforms Inc. as it demonstrated a Power Inflow at a price of $582.40. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Meta&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Meta&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for Meta, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data are brought to you by Benzinga APIs</a> and include firms, like <a href="https://finitusa.com/en/">Finit USA</a>, responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $582.40. The returns on the High price ($596.52) and Close price ($595.94) after the Power Inflow were respectively 2.4% and 2.3%%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. In this case the high of the day and close were very close but that is not always the case
Past Performance is Not Indicative of Future Results

Signals

Markets

Tradepulse Power Inflow Alert: Meta Platforms Inc. Receives Signal And Climbs Over 2.4% On The Day

Throughout the last three months, 7 analysts have evaluated Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $59.57, a high estimate of $65.00, and a low estimate of $54.00. Witnessing a positive shift, the current average has risen by 17.56% from the previous average price target of $50.67.
<img src="https://www.benzinga.com/files/images/story/2024/1728075764_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Newmont is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Murphy</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$63.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Daniel Major</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>David Coleman</td>
<td>Argus Research</td>
<td>Announces</td>
<td>Buy</td>
<td>$58.00</td>
<td>-</td>
</tr>
<tr>
<td>Tanya Jakusconek</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$59.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Jackie Przybylowski</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$57.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Matthew Murphy</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$54.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Anita Soni</td>
<td>CIBC</td>
<td>Raises</td>
<td>Outperformer</td>
<td>$61.00</td>
<td>$46.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Newmont. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Newmont compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Newmont's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Newmont's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NEM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Newmont analyst ratings.</a>
<h2>About Newmont</h2>
Newmont is the world's largest gold miner. It bought Goldcorp in 2019, combined its Nevada mines in a joint venture with competitor Barrick later that year, and also purchased competitor Newcrest in November 2023. Its portfolio includes 17 wholly or majority owned mines and interests in two joint ventures in the Americas, Africa, Australia and Papua New Guinea. The company is expected to produce roughly 6.9 million ounces of gold in 2024. However, after buying Newcrest, Newmont is likely to sell a number of its higher cost, smaller mines accounting for 20% of forecast sales in 2024. Newmont also produces material amounts of copper, silver, zinc, and lead as byproducts. It had about two decades of gold reserves along with significant byproduct reserves at the end of December 2023.
<h3>Newmont's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Positive Revenue Trend: Examining Newmont's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 64.07% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Newmont's net margin excels beyond industry benchmarks, reaching 19.38%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.93%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Newmont's ROA stands out, surpassing industry averages. With an impressive ROA of 1.54%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Newmont's debt-to-equity ratio stands notably higher than the industry average, reaching 0.31. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 7 Analyst Ratings Have To Say About Newmont

During the last three months, 12 analysts shared their evaluations of Lumentum Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $59.83, along with a high estimate of $70.00 and a low estimate of $40.00. Marking an increase of 13.42%, the current average surpasses the previous average price target of $52.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1728075755_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Lumentum Holdings by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simon Leopold</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Tim Savageaux</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$50.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>George Notter</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Richard Shannon</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$54.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$40.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Dave Kang</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Mike Genovese</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$69.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Alex Henderson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$70.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Lumentum Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Lumentum Holdings compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Lumentum Holdings's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LITE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Lumentum Holdings analyst ratings.</a>
<h2>All You Need to Know About Lumentum Holdings</h2>
Lumentum Holdings Inc is a California-based technology firm. The company provides two types of optical and photonic products: optical components that are used in telecommunications networking equipment, and commercial lasers for manufacturing, inspection, and life-science lab uses. Its segments are Optical Communications and Commercial Lasers. The firm is also expanding into new optical applications, such as 3-D sensing laser diode for consumer electronics. It generates maximum revenue from the OpComms segment. The OpComms segment products include a wide range of components, modules, and subsystems to support customers including carrier networks for access (local), metro (intracity), long-haul, and submarine (undersea) applications.
<h3>Unraveling the Financial Story of Lumentum Holdings</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, Lumentum Holdings faced challenges, resulting in a decline of approximately -16.86% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Lumentum Holdings's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -81.9%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Lumentum Holdings's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -23.66%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Lumentum Holdings's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -6.21%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Lumentum Holdings's debt-to-equity ratio stands notably higher than the industry average, reaching 2.67. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LITE

Assessing Lumentum Holdings: Insights From 12 Financial Analysts

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Quanta Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Quanta Services and provided 12-month price targets. The average target is $297.0, accompanied by a high estimate of $348.00 and a low estimate of $256.00. This upward trend is evident, with the current average reflecting a 3.28% increase from the previous average price target of $287.57.
<img src="https://www.benzinga.com/files/images/story/2024/1728075736_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of Quanta Services's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$348.00</td>
<td>$302.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$256.00</td>
<td>-</td>
</tr>
<tr>
<td>Marc Bianchi</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$280.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$319.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Gus Richard</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$280.00</td>
<td>$264.00</td>
</tr>
<tr>
<td>Alex Rygiel</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$303.00</td>
<td>$286.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$302.00</td>
<td>$299.00</td>
</tr>
<tr>
<td>Andrew Wittmann</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$288.00</td>
<td>$287.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Quanta Services. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Quanta Services compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Quanta Services's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Quanta Services's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PWR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Quanta Services analyst ratings.</a>
<h2>Discovering Quanta Services: A Closer Look</h2>
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under three reportable segments: electric power, renewables infrastructure, and underground utility and infrastructure.
<h3>Quanta Services: A Financial Overview</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Quanta Services showcased positive performance, achieving a revenue growth rate of 10.81% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 3.36%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.91%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Quanta Services's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.2%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.58, Quanta Services adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

8 Analysts Assess Quanta Services: What You Need To Know

In the preceding three months, 12 analysts have released ratings for American Intl Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $85.25, a high estimate of $93.00, and a low estimate of $77.00. Observing a 0.08% increase, the current average has risen from the previous average price target of $85.18. 
<img src="https://www.benzinga.com/files/images/story/2024/1728075681_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of American Intl Gr by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Zaremski</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$90.00</td>
<td>-</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$80.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$77.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Paul Newsome</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$86.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Joshua Shanker</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$82.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Michael Ward</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$87.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Joshua Shanker</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$81.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$93.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Michael Phillips</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Scott Heleniak</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$87.00</td>
<td>$87.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to American Intl Gr. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of American Intl Gr compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for American Intl Gr's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of American Intl Gr's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AIG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on American Intl Gr analyst ratings.</a>
<h2>Delving into American Intl Gr's Background</h2>
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. The company recently spun off its life insurance operations (Corebridge), but still retains a majority stake.
<h3>American Intl Gr: Financial Performance Dissected</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Negative Revenue Trend: Examining American Intl Gr's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -11.75% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: American Intl Gr's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -60.38%, the company may face hurdles in effective cost management.
Return on Equity (ROE): American Intl Gr's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -9.06%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.12%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.22, American Intl Gr adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: American Intl Gr In The Eyes Of 12 Experts

The U.S. Department of Justice (DOJ) is holding firm on its stance that medical marijuana users should not allowed to own a gun, citing safety risks.
In a recent filing, federal attorneys argued that the <a href="https://www.benzinga.com/markets/cannabis/24/06/39488414/cannabis-guns-kentucky-2nd-amendment-meet-the-atf-if-you-say-yes-to-medical-marijuana-the-answer">ban on gun ownership</a> for cannabis users is constitutional and should remain in place. 
This aligns with federal regulations barring gun access for individuals considered potentially dangerous, such as those who are mentally ill or under the influence, <a href="https://www.marijuanamoment.net/doj-says-allowing-a-pennsylvania-prosecutor-who-uses-medical-marijuana-to-possess-a-gun-would-be-dangerous/">reported</a> Marijuana Moment.
<h3 class="wp-block-heading">Pennsylvania Prosecutor Challenges Federal Gun Ban</h3>
This filing responds to <a href="https://www.benzinga.com/markets/cannabis/24/01/36750779/guns-and-weed-conflict-heats-up-pennsylvania-da-sues-feds-over-firearms-ban-for-medical-marijuan">a lawsuit</a> by Robert Greene, the District Attorney of Warren County, Pennsylvania, who is a registered medical marijuana patient. Along with the Second Amendment Foundation, Greene filed suit against the DOJ, Attorney General Merrick Garland and other federal agencies, arguing that the ban infringes on his right to bear arms for self-defense.
The DOJ&#8217;s filing, submitted to the U.S. District Court for the Western District of Pennsylvania, seeks to dismiss Greene&#8217;s suit. 
"Marijuana's physical and mental effects impair a person's judgment, including judgment about whether to use firearms," it says.
The next step for Robert Greene's case involves a federal court decision on his request for a preliminary injunction.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/03/37823911/cannabis-and-guns-legal-battle-heats-up-as-feds-block-weapons-sales-over-weed-smell-lawsuits-ens">Cannabis And Guns: Legal Battle Heats Up As Feds Block Weapons Sales Over Weed Smell, Lawsuits Ensue</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Contradictory Ruling In Texas Gun &amp; Cannabis Rights Case</h3>
Greene's case is not the only legal battle on this issue. In a separate case, the 5th U.S. Circuit Court of Appeals ruled that cannabis users cannot be barred from owning firearms.
The ruling arose from <a href="https://www.benzinga.com/markets/cannabis/24/08/40655441/cannabis-users-cannot-be-barred-from-gun-ownership-u-s-appeals-court-rules">the case</a> of Paola Connelly, a Texas resident whose right to bear arms was upheld despite her past marijuana use. "Marijuana user or not, Paola is a member of our political community and thus has a presumptive right to bear arms," U.S. Circuit Judge Kurt Engelhardt ruled.
The decision is significant because it aligns with <a href="https://www.benzinga.com/markets/cannabis/23/08/33719970/federal-court-strikes-down-gun-prohibition-for-cannabis-users-as-unconstitutional">a 2022 Supreme Court</a> decision stating that firearm laws should reflect historical gun ownership traditions.
While the DOJ has not commented on this ruling, it raises questions about how the federal government will address gun ownership rights among the millions of legal cannabis users nationwide.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/08/40655441/cannabis-users-cannot-be-barred-from-gun-ownership-u-s-appeals-court-rules">Cannabis Users Cannot Be Barred From Gun Ownership, U.S. Appeals Court Rules </a></li>
</ul>
Cover: AI generated image

Cannabis

Government

Regulations

Politics

Legal

Justice Department Defends Ban On Gun Ownership For Medical Cannabis Users

Investors with a lot of money to spend have taken a bullish stance on Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with SBUX, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Starbucks.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 12%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $26,650, and 7, calls, for a total amount of $435,875.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $75.0 to $100.0 for Starbucks during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Starbucks's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Starbucks's whale activity within a strike price range from $75.0 to $100.0 in the last 30 days. 
<h3>Starbucks Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728074755_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$7.8</td>
<td>$7.7</td>
<td>$7.75</td>
<td>$100.00</td>
<td>$155.0K</td>
<td>4.2K</td>
<td style="text-align: right;">203</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.15</td>
<td>$8.1</td>
<td>$8.15</td>
<td>$95.00</td>
<td>$86.3K</td>
<td>1.3K</td>
<td style="text-align: right;">126</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$2.83</td>
<td>$2.75</td>
<td>$2.75</td>
<td>$100.00</td>
<td>$50.6K</td>
<td>10.5K</td>
<td style="text-align: right;">213</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$17.45</td>
<td>$17.3</td>
<td>$17.38</td>
<td>$80.00</td>
<td>$43.5K</td>
<td>6.6K</td>
<td style="text-align: right;">27</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$21.1</td>
<td>$20.45</td>
<td>$21.04</td>
<td>$75.00</td>
<td>$42.0K</td>
<td>174</td>
<td style="text-align: right;">12</td>
</tr>
</tbody>
</table>

<h3>About Starbucks</h3>
Starbucks is one of the most widely recognized restaurant brands in the world, operating more than 38,000 stores across more than 80 countries as of the end of fiscal 2023. The firm operates in three segments: North America, international markets, and channel development (grocery and ready-to-drink beverage). The coffee chain generates revenue from company-operated stores, royalties, sales of equipment and products to license partners, ready-to-drink beverages, packaged coffee sales, and single-serve products.
In light of the recent options history for Starbucks, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Starbucks Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 5,418,853, with SBUX's price up by 1.13%, positioned at $96.64.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 27 days.</li>
</ul>
<h3>Expert Opinions on Starbucks</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $104.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Bernstein has elevated its stance to Outperform, setting a new price target at $115. 
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Starbucks, maintaining a target price of $105. 
&#x2A; An analyst from BMO Capital persists with their Outperform rating on Starbucks, maintaining a target price of $110. 
&#x2A; An analyst from Jefferies downgraded its action to Underperform with a price target of $76. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Starbucks with a target price of $118. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Starbucks, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

SBUX

Check Out What Whales Are Doing With SBUX

Financial giants have made a conspicuous bearish move on Dollar Tree. Our analysis of options history for Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) revealed 9 unusual trades.
Delving into the details, we found 33% of traders were bullish, while 66% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $60,260, and 7 were calls, valued at $925,315.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $55.0 to $100.0 for Dollar Tree over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Dollar Tree stands at 686.0, with a total volume reaching 13,653.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Dollar Tree, situated within the strike price corridor from $55.0 to $100.0, throughout the last 30 days.
<h3>Dollar Tree 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728074750_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DLTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.83</td>
<td>$2.65</td>
<td>$2.69</td>
<td>$85.00</td>
<td>$416.9K</td>
<td style="text-align: right;">730</td>
<td>1.5K</td>
</tr>
<tr>
<td>DLTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.81</td>
<td>$2.67</td>
<td>$2.69</td>
<td>$85.00</td>
<td>$269.0K</td>
<td style="text-align: right;">730</td>
<td>2.5K</td>
</tr>
<tr>
<td>DLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$9.3</td>
<td>$9.2</td>
<td>$9.25</td>
<td>$75.00</td>
<td>$71.2K</td>
<td style="text-align: right;">240</td>
<td>79</td>
</tr>
<tr>
<td>DLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.8</td>
<td>$2.78</td>
<td>$2.77</td>
<td>$85.00</td>
<td>$65.9K</td>
<td style="text-align: right;">730</td>
<td>2.9K</td>
</tr>
<tr>
<td>DLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.81</td>
<td>$2.75</td>
<td>$2.78</td>
<td>$85.00</td>
<td>$45.1K</td>
<td style="text-align: right;">730</td>
<td>2.7K</td>
</tr>
</tbody>
</table>

<h3>About Dollar Tree</h3>
Dollar Tree operates discount stores across the United States and Canada, with over 8,600 shops under its namesake banner and nearly 7,800 under Family Dollar. About 47% of Dollar Tree's sales in fiscal 2023 were composed of consumables (including food, health and beauty, and cleaning products), around 45% from variety items (including toys and homewares), and over 5% from seasonal items. The Dollar Tree banner sells most of its merchandise at the $1.25 price point and positions its stores in well-populated suburban markets. Conversely, Family Dollar primarily sells consumable merchandise (80% of the banner's sales) at prices below $10. About two-thirds of Family Dollar's stores are located in urban and suburban markets, with the remaining one-third located in rural areas.
After a thorough review of the options trading surrounding Dollar Tree, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Dollar Tree's Current Market Status</h3>
<ul>
<li>With a trading volume of 3,407,814, the price of DLTR is up by 2.63%, reaching $70.9.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 54 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Dollar Tree</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $80.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from BMO Capital has revised its rating downward to Market Perform, adjusting the price target to $68. 
&#x2A; An analyst from Melius Research downgraded its action to Hold with a price target of $70. 
&#x2A; Consistent in their evaluation, an analyst from Evercore ISI Group keeps a In-Line rating on Dollar Tree with a target price of $78. 
&#x2A; An analyst from Loop Capital downgraded its action to Hold with a price target of $65. 
&#x2A; An analyst from Guggenheim persists with their Buy rating on Dollar Tree, maintaining a target price of $120. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Dollar Tree with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

DLTR

This Is What Whales Are Betting On Dollar Tree

Financial giants have made a conspicuous bearish move on Cava Group. Our analysis of options history for Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) revealed 11 unusual trades.
Delving into the details, we found 18% of traders were bullish, while 72% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $84,462, and 9 were calls, valued at $1,730,287.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $60.0 to $140.0 for Cava Group over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Cava Group's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Cava Group's whale trades within a strike price range from $60.0 to $140.0 in the last 30 days. 
<h3>Cava Group Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728074744_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$64.9</td>
<td>$64.8</td>
<td>$64.8</td>
<td>$60.00</td>
<td>$1.2M</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$12.1</td>
<td>$12.0</td>
<td>$12.0</td>
<td>$135.00</td>
<td>$114.0K</td>
<td style="text-align: right;">547</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$3.6</td>
<td>$3.3</td>
<td>$3.57</td>
<td>$126.00</td>
<td>$71.9K</td>
<td style="text-align: right;">237</td>
<td style="text-align: right;">234</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$14.9</td>
<td>$14.2</td>
<td>$14.1</td>
<td>$125.00</td>
<td>$70.5K</td>
<td style="text-align: right;">909</td>
<td style="text-align: right;">51</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/11/24</td>
<td>$2.95</td>
<td>$2.65</td>
<td>$2.65</td>
<td>$128.00</td>
<td>$53.0K</td>
<td style="text-align: right;">56</td>
<td style="text-align: right;">241</td>
</tr>
</tbody>
</table>

<h3>About Cava Group</h3>
Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates the majority of its revenue from the CAVA segment.
In light of the recent options history for Cava Group, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Cava Group</h3>
<ul>
<li>Currently trading with a volume of 1,895,183, the CAVA's price is up by 1.38%, now at $126.65. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 32 days.</li>
</ul>
<h3>Professional Analyst Ratings for Cava Group</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $127.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from TD Securities keeps a Buy rating on Cava Group with a target price of $130. 
&#x2A; An analyst from TD Cowen downgraded its action to Buy with a price target of $115. 
&#x2A; An analyst from TD Cowen has decided to maintain their Buy rating on Cava Group, which currently sits at a price target of $130. 
&#x2A; Maintaining their stance, an analyst from Argus Research continues to hold a Buy rating for Cava Group, targeting a price of $128. 
&#x2A; In a cautious move, an analyst from UBS downgraded its rating to Neutral, setting a price target of $135. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Cava Group, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

CAVA

Decoding Cava Group's Options Activity: What's the Big Picture?

Contracts

NPWR

NET Power Says Payments For Long-lead Materials Under Original Letter Of Limited Notice To Proceed Commenced In December 2023; Remainder Of Payments Under LNTP Are Expected To Continue To Be Made Through April 2026

&#8220;We've seen this movie before,&#8221; Al Harrington says in an exclusive interview with <a href="https://www.benzinga.com/cannabis">Benzinga Cannabis</a>, displaying the conviction of someone who's lived through the consequences of history. The former NBA player turned cannabis entrepreneur knows all too well how power structures have shaped — and dismantled — opportunities for communities of color. As we delve into the war on drugs and its enduring effects, Harrington's stance is clear. The criminalization of cannabis wasn't about safety; it was about control.
The people who once faced incarceration for cannabis possession are now fighting for a seat at the table in an industry generating billions. &#8220;At one point, the lottery was illegal, alcohol was illegal, but what's really unique is when you do your research, people of color started all those industries as well and have no ownership in it,&#8221; Harrington reflects. He's determined to ensure history doesn't repeat itself in the cannabis space.
Harrington's mission is rooted in advocacy. &#8220;We've seen this movie before,&#8221; he continues, &#8220;and that's what inspired me to be a crusader, trying to make sure we don't forget the people that really created this industry.&#8221; His focus is clear: inclusion for communities of color, particularly those harmed by the war on drugs, and the opportunity to build generational wealth.
<h3 class="wp-block-heading">Nixon's Ignorance And Corporate Interests</h3>
The war on drugs was largely shaped by former U.S. President Richard Nixon, whose administration spearheaded aggressive criminalization policies. Recently resurfaced <a href="https://www.benzinga.com/markets/cannabis/24/09/40869408/richard-nixon-secretly-admitted-marijuana-is-not-particularly-dangerous-new-tapes-reveal">comments revealed that Nixon didn't even consider marijuana particularly dangerous</a>. Harrington reacts to this revelation with a sense of incredulity. &#8220;It was obviously ignorance,&#8221; he says.
Harrington highlights the political forces that may have influenced Nixon&#8217;s policies. &#8220;A lot of decisions that are made by people like that are usually influenced by others,&#8221; he explains. Industries like paper and lumber, threatened by the versatility of hemp, likely played a role in cannabis becoming a Schedule I drug, ranked alongside heroin and cocaine. &#8220;At that time, people paid less on their taxes if they produced hemp,&#8221; Harrington said. &#8220;And then it becomes a Schedule I drug with heroin and cocaine — that doesn't even make sense.&#8221;
For Harrington, the criminalization of cannabis is a prime example of how the system has worked against communities of color. He's well aware of how prohibition has kept Black and Brown people out of the cannabis industry, an industry they were once heavily involved in—illegally. But legalization brings a chance to rectify those wrongs. &#8220;We don't forget the people that were mostly harmed and negatively affected by it, and making sure as all these billions of dollars are gonna be made, that we at least have the opportunity for this generational wealth just like our counterparts,&#8221; he told Benzinga.
<h3 class="wp-block-heading">Pressure From Big Pharma And Corporate Giants</h3>
As our conversation shifts to the role of interest groups and Big Pharma in the cannabis space, Harrington acknowledges the challenges ahead. With over a decade of experience in the industry, he's seen the changing dynamics as federal legalization becomes a looming reality. However, Harrington notes that he hasn't personally felt pressure from these groups. &#8220;I haven't felt any of the pressure from any of those groups,&#8221; suggesting that his platform may have insulated him from some corporate tactics.
Still, Harrington is not naive about the interests at play. He recognizes that pharmaceutical companies face challenges with cannabis, largely due to its natural growth cycle. &#8220;Cannabis takes four months to grow, no matter how you look at it,&#8221; he explains, contrasting it with the rapid production of pharmaceutical drugs. &#8220;These other drugs they make, it takes seconds.&#8221;
Despite these challenges, Harrington believes Big Pharma is closely watching the cannabis space, and when federal legalization arrives, it will move aggressively. &#8220;They're gonna buy in as soon as it's federally legal,&#8221; he predicts. &#8220;They're just waiting for that time, and then they're gonna come in like gangbusters, buying up everything.&#8221;
Harrington remains committed to fighting for the integrity of the plant. &#8220;We want to continue to fight to keep it as authentic and natural and organic as possible because this plant is supposed to grow in the sun, not in a lab.&#8221; For him, cannabis is more than a commodity, it&#8217;s a cultural and medicinal symbol that has deep roots in marginalized communities.
<h3 class="wp-block-heading">Protecting Cannabis For The Future</h3>
For Harrington, the fight against corporate interests is about more than just business—it's about protecting the integrity of the cannabis plant and ensuring that those who have been in the industry for the right reasons don&#8217;t get pushed out by large corporations. &#8220;I don't think that it can really capture all the benefits unless it's in that state,&#8221; he says, emphasizing the importance of growing cannabis under natural conditions.
Harrington's dedication to the plant, combined with his drive to create opportunities for communities of color, positions him as both an advocate and protector of what cannabis should be. As the industry continues to evolve, with federal legalization on the horizon, Harrington's focus remains clear: he's not just building a business; he's building a legacy. And for him, that legacy is about much more than money. It's about ensuring that the people who have been marginalized by the war on drugs have a stake in the industry's future—and that cannabis remains a force for healing, empowerment and equity.

Sports

Exclusives

Interview

EXCLUSIVE - Al Harrington: Nixon's Cannabis Policies Were Driven By Corporate Interests, Ignorance

On Sept 30, NET Power's Unit & Baker Hughes Energy Services Entered Into Variation Agreement No. 2; Pursuant To LNTP, Co Will Pay Baker Hughes Up To About $90M For Purchase Of Long-Lead Materials

Management

CING

On Sept 23, Cingulate Shane Schaffer, CEO & Chairman Of Co Was Charged With One Count Of "Aggravated Domestic Battery"

NXST

On Sept 30, Nexstar Media Group Notified Michael Strober That It Eliminated His Position Of Executive Vice President & Chief Revenue Officer

DBGI

On Oct 2, Digital Brands Group Got Notice Of Delisting Of Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq

Bit Digital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) ("Bit Digital" or the "Company"), a sustainable platform for digital assets and artificial intelligence ("AI") infrastructure headquartered in New York, announced its unaudited digital asset production, HPC services revenue, and corporate updates for the month of September 2024.
Corporate Highlights for September 2024
<ul>
<li>The Company had 256 servers actively generating revenue from its initial Bit Digital AI contract, as of September 30, 2024. The Company earned approximately $4.2 million of unaudited revenue from this contract during the month of September 2024.</li>
<li>In September 2024, the Company produced 51.5 BTC, a 3.6% decrease compared to the prior month.</li>
<li>The Company's active hash rate was approximately 2.43 EH/s as of September 30, 2024.</li>
<li>Treasury holdings of&nbsp;BTC and ETH were 731.3 and 27,388.9 with a fair market value of approximately $46.3 million and $71.3 million, respectively, on September 30, 2024.</li>
<li>The&nbsp;BTC equivalent[1] of our digital asset holdings as of September 30, 2024, was approximately 1,863.0 or approximately $118.0 million.</li>
<li>The Company had cash and cash equivalents of $104.0 million and total liquidity (defined as cash and cash equivalents,&nbsp;USDC, and the fair market value of digital assets) of approximately $222.0 million, as of September 30, 2024.</li>
</ul>

BTBT

Bit Digital Announces It Produced 51.5 BTC, A 3.6% Decrease MoM; Earned ~$4.2M Of Unaudited Revenue From This Contract During The Month Of September 2024

Bob Jornayvaz Steps Down as Chief Executive Officer and Director Following Extended Medical Leave of Absence
Intrepid Potash, Inc. ("Intrepid," "we," "the Company" or "our") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPI#NYSE">IPI</a>) today announced that Bob Jornayvaz has stepped down as Chief Executive Officer and as a Director of the Board following his extended medical leave of absence.
"We are thankful to Bob for his immeasurable contributions to the Company over the last two decades," said Barth Whitham, Chair of the Board. "Bob led numerous initiatives that strengthened our customer relationships, modernized our operations, and capitalized on our unique position as the only domestic producer of potash. He took great pride in the Company and its contributions to the domestic and global agriculture industry. Bob and his family remain in our thoughts, and we continue to wish him well in his recovery."
Intrepid's Chief Financial Officer, Matt Preston, will continue to serve as acting principal executive officer as the Board of Directors' search to identify a successor Chief Executive Officer remains ongoing. Mr. Whitham continued, "The Board's search for a CEO is well underway. In the interim, we are pleased to continue to have Matt and the rest of the management team lead the execution of Intrepid's strategic plan."

Intrepid Potash Announces Bob Jornayvaz Steps Down As Chief Executive Officer And Director Following Extended Medical Leave Of Absence; CFO, Matt Preston, Will Continue To Serve As Acting Principal Executive Officer As The Board Of Directors' Search To Identify A Successor Chief Executive Officer Remains Ongoing

Entero Therapeutics (ENTO) just unveiled an announcement. Entero Therapeutics, Inc. has announced a strategic shift in their executive team, with D...

Entero Therapeutics Executive Team Strategic Reshuffle

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Thursday as we dig into all of the news moving shares this morning!



Moving stocks are public offering updates, new investments an earnings report and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Assure (NASDAQ:<a href="https://investorplace.com/stock-quotes/ionm-stock-quote/">IONM</a>) stock is rocketing more than 128% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318417463&amp;type=PDF&amp;symbol=IONM&amp;cdn=8d8708e472ad2a1117d6e2e1ea234033&amp;companyName=Assure+Holdings+Corp.&amp;formType=RW&amp;formDescription=Registration+Withdrawal+Request&amp;dateFiled=2024-06-26">withdrawing a proposed public offering</a>.</li>



<li>Vigil Neuroscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/vigl-stock-quote/">VIGL</a>) shares are soaring over 40% on a <a href="https://www.globenewswire.com/news-release/2024/06/27/2904902/0/en/Vigil-Neuroscience-Announces-40-Million-Strategic-Investment-from-Sanofi.html">$40 million investment</a>.</li>



<li>CASI Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/casi-stock-quote/">CASI</a>) stock is surging more than 31% on a <a href="https://www.prnewswire.com/news-releases/casi-pharmaceuticals-announces-15-million-private-placement-financing-by-venrock-healthcare-capital-partners-foresite-capital-panacea-venture-and-dr-wei-wu-he-302183230.html">$15 million private placement</a>.</li>



<li>Entero Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ento-stock-quote/">ENTO</a>) shares are gaining over 26% on a <a href="https://www.nasdaq.com/press-release/entero-therapeutics-announces-peer-reviewed-publication-unveiling-novel-algorithm">peer-reviewed publication</a>.</li>



<li>Faraday Future (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) stock is increasing more than 24% as it <a href="https://investorplace.com/2024/06/faraday-future-ffie-stock-soars-80-following-rivian-volkswagen-deal/">continues a recent rally</a>.</li>



<li>Incannex Healthcare (NASDAQ:<a href="https://investorplace.com/stock-quotes/ixhl-stock-quote/">IXHL</a>) shares are jumping over 23% despite a lack of news this morning.</li>



<li>Geovax Labs (NASDAQ:<a href="https://investorplace.com/stock-quotes/govx-stock-quote/">GOVX</a>) stock is climbing more than 21% without any clear news this morning.</li>



<li>Fresh Vine Wine (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vine-stock-quote/">VINE</a>) shares are heading close to 17% higher with heavy pre-market trading.</li>



<li>Phunware (NASDAQ:<a href="https://investorplace.com/stock-quotes/phun-stock-quote/">PHUN</a>) stock is getting an over 15% boost without any obvious news to report.</li>



<li>Hyzon Motors (NASDAQ:<a href="https://investorplace.com/stock-quotes/hyzn-stock-quote/">HYZN</a>) shares are up nearly 15% with strong trading this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Branchout Food (NASDAQ:<a href="https://investorplace.com/stock-quotes/bof-stock-quote/">BOF</a>) stock is plummeting more than 37% after <a href="https://www.nasdaq.com/press-release/branchout-food-prices-14-million-follow-public-offering-2024-06-26">pricing a follow-on offering</a>.</li>



<li>Tonix Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/tnxp-stock-quote/">TNXP</a>) shares are diving over 28% on a <a href="https://www.stocktitan.net/news/TNXP/tonix-pharmaceuticals-announces-proposed-public-d6yhuinwfxm9.html">proposed public offering</a>.</li>



<li>Bluejay Diagnostics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bjdx-stock-quote/">BJDX</a>) stock is tumbling more than 21% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318418078&amp;type=PDF&amp;symbol=BJDX&amp;cdn=14a15ef82de2ebc313ddbbf7cad3f31c&amp;companyName=Bluejay+Diagnostics+Inc.&amp;formType=EFFECT&amp;formDescription=Notice+of+Effectiveness&amp;dateFiled=2024-06-26">effecting a public offering</a>.</li>



<li>Immutep (NASDAQ:<a href="https://investorplace.com/stock-quotes/immp-stock-quote/">IMMP</a>) shares are taking an over 17% beating without any apparent news today.</li>



<li>VSee Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsee-stock-quote/">VSEE</a>) stock is slipping more than 17% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318417950&amp;type=PDF&amp;symbol=VSEE&amp;cdn=a8750adb0a7c7d12db86db6bfac8e49b&amp;companyName=VSee+Health+Inc.&amp;formType=4&amp;formDescription=Statement+of+changes+in+beneficial+ownership+of+securities&amp;dateFiled=2024-06-26">alongside recent insider trading</a>.</li>



<li>Swvl (NASDAQ:<a href="https://investorplace.com/stock-quotes/swvl-stock-quote/">SWVL</a>) shares are dropping over 16% on Thursday morning.</li>



<li>Levi Strauss (NYSE:<a href="https://investorplace.com/stock-quotes/levi-stock-quote/">LEVI</a>) stock is decreasing more than 16% with its <a href="https://www.cnbc.com/2024/06/26/levi-levi-earnings-q2-2024.html">Q2 earnings report</a>.</li>



<li>International Paper (NYSE:<a href="https://investorplace.com/stock-quotes/ip-stock-quote/">IP</a>) shares are falling over 15% today.</li>



<li>Recursion Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/rxrx-stock-quote/">RXRX</a>) stock is slipping more than 14% after <a href="https://www.stocktitan.net/news/RXRX/recursion-announces-pricing-of-200-million-public-offering-of-class-49il22g17787.html">pricing a public offering</a>.</li>



<li>KraneShares California Carbon Allowance Strategy ETF (NYSEARCA:<a href="https://investorplace.com/stock-quotes/kcca-stock-quote/">KCCA</a>) shares close out our pre-market stock movers down over 13%. </li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-june-27th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

The latest announcement is out from Entero Therapeutics (ENTO). Entero Therapeutics, Inc. announced that Dr. Jack Syage, the Chief Scientific Offic...

Entero Therapeutics CSO Resigns Amid Cost-Cutting Strategy

Entero Therapeutics files secondary offering of 3.5M shares

Entero Therapeutics (ENTO) has provided an announcement. Entero Therapeutics, Inc. has announced through a press release by CEO James Sapirstein a ...

Entero Therapeutics Issues Shareholder Update Letter

The latest announcement is out from Entero Therapeutics (ENTO). Entero Therapeutics, Inc. is navigating financial turmoil after its subsidiary Immu...

Entero Therapeutics Grapples with Financial Strain and Compliance Issues

Entero Therapeutics (ENTO) just unveiled an announcement. Timothy R. Ramdeen, a seasoned professional with nearly a decade of experience in private...

Entero Therapeutics Welcomes Timothy Ramdeen to Board

Entero Therapeutics receives Nasdaq notification regarding delayed form 10-Q

An announcement from Entero Therapeutics ( ($ENTO) ) is now available. Entero Therapeutics, a clinical-stage biopharmaceutical company, has announc...

Entero Therapeutics Strikes Deal for Drug Trial Compliance Tech

BJDX

CASI

ENTO

FFIE

GOVX

HYZN

IMMP

IONM

IXHL

KCCA

LEVI

PHUN

RXRX

SWVL

TNXP

VIGL

VINE

VSEE

Press Releases

First Wave BioPharma Changes Name to Entero Therapeutics

Health Care

Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference

Biotech

General

Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention

Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease

Entero Therapeutics Announces Abstract on Celiac Disease Research Accepted for Presentation at the 20th International Celiac Disease Symposium

Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds

Entero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program

Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q

Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings

Comments

Entero Therapeutics

Interés en corto

Entero Therapeutics (NASDAQ:ENTO) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL